IN Brief:
- dsm-firmenich and Italian startup Nous are accelerating the commercial development of Koncentra.
- The soluble botanical ingredient is designed for low dose use with limited effects on taste, colour, and turbidity.
- Clinical trials, regulatory work, claims substantiation, and application development will support international deployment.
dsm-firmenich and Nous have formed a strategic partnership to accelerate commercial development of Koncentra, a caffeine free botanical ingredient intended for energy, concentration, and mood applications.
The agreement extends dsm-firmenich’s investment in the Italian startup and combines Nous’s extraction technology with clinical research, regulatory support, formulation expertise, claims development, and international market access.
Koncentra is produced through a proprietary extraction process designed to preserve selected bioactive compounds while delivering repeatable composition at industrial scale. A low recommended dose and high solubility are intended to limit effects on taste, colour, and turbidity when the ingredient enters a finished formulation.
Potential applications include functional drinks, powdered beverages, shots, bars, snacks, and products seeking energy or cognitive positioning without relying entirely on caffeine. Application work will examine behaviour under different pH levels, heat treatments, storage conditions, and packaging systems.
Clinical trial design and the substantiation of energy, cognitive, and physical performance claims will form part of the development programme. Regulatory work will run alongside those trials because ingredient status, permitted wording, maximum use levels, and botanical claims differ widely between markets.
Turning a development ingredient into a repeatable factory input requires control over the variation found in botanical raw materials. Variety, cultivation, harvest timing, geography, storage, and extraction conditions can all affect composition, so standardisation must narrow those differences before a manufacturer can use one process setting across successive batches.
High solubility removes one common difficulty but does not eliminate formulation work. Botanical extracts can interact with acids, proteins, minerals, sweeteners, preservatives, flavours, and colours, while bitterness, astringency, haze, sediment, or instability may appear only after heat treatment or extended shelf life.
Functional energy moves beyond stimulant loading
Caffeine remains the dominant active ingredient across energy drinks, shots, sports nutrition, and functional powders because its effects are familiar, measurable, and comparatively easy to formulate. Product development is nevertheless widening towards later day consumption, lower stimulant intake, and combined energy, mood, and concentration claims.
Botanical ingredients can support that expansion, although their commercial prospects depend less on a familiar plant name than on dose, extraction method, bioactive content, sensory performance, and evidence capable of supporting a lawful claim. Consumers may recognise the ingredient, but factories and regulators require a reproducible specification.
dsm-firmenich estimates that 68% of consumers globally are concerned about daily energy levels. Energy claims already account for a substantial share of functional beverage development, while brain and nerve support has become a related growth area across drinks, powders, supplements, and snacks.
Manufacturing economics will depend on the balance between efficacy, sensory performance, and cost in use. Concentrated material reduces the quantity required in each batch, yet extraction, standardisation, clinical work, and regulatory support can make each kilogram considerably more expensive than a conventional stimulant.
Low dose use can reduce storage and handling volume, although it also increases the need for accurate metering. A small absolute deviation becomes proportionally more significant where only a limited amount enters each batch, favouring controlled premixes, verified feeders, and validated blending times.
Application demands will differ markedly between categories. Bars and snacks expose botanical ingredients to baking, extrusion, fat systems, low water activity, and uneven distribution, while beverages create separate challenges around dissolution, pasteurisation, carbonation, light exposure, and sediment control.
A similar need for industrial standardisation sits behind Del Monte and Treatt’s conversion of fruit side streams into beverage extracts. In both cases, naturally variable material must become a stable ingredient with controlled composition, predictable flavour, and dependable processing behaviour.
Claims will determine how clearly finished products can communicate the intended benefit. Even where clinical evidence supports Koncentra, manufacturers must ensure that the tested dose, study population, product format, and permitted language correspond with the formulation entering each market.
International launches will therefore require the ingredient specification, safety evidence, technical file, artwork, and marketing language to move together. A claim accepted in one jurisdiction may require different wording, a modified dose, or a different product classification elsewhere.
Scale-up will place further pressure on raw material sourcing. Contract cultivation, harvest conditions, traceability, and extraction capacity must expand without allowing the bioactive profile or contaminant risk to drift as volumes increase.
The partnership gives Nous access to the clinical, regulatory, and applications infrastructure required to move beyond startup scale. Commercial adoption will depend on whether Koncentra retains consistent performance through industrial processing, supports defendable claims, and reaches a cost in use compatible with more than a narrow premium segment.
